Program
Estradiol
Also written as “NOMAC-E2”, “estradiol, 25 mcg” and “estradiol, 10 mcg”.
Its studies are mostly in Hot Flashes · Dyspareunia · Atrophic Vaginitis · Leiomyoma · Menorrhagia, led by 21 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 120 open or running | phase 4since Oct 8, 2012 | Apr 19, 2005 | none ahead |
| Bayer | 100 open or running | phase 4since Sep 12, 2005 | Sep 9, 2005 | none ahead |
| AbbVie | 80 open or running | phase 3since Feb 17, 2010 | Feb 17, 2010 | none ahead |
| Teva Pharmaceutical Industries | 30 open or running | phase 3since Nov 7, 2022 | Jul 2, 2010 | none ahead |
| TherapeuticsMD | 30 open or running | phase 3since Sep 5, 2013 | Sep 5, 2013 | none ahead |
| Grünenthal | 20 open or running | phase 1since Nov 9, 2018 | Nov 9, 2018 | none ahead |
| Merck | 20 open or running | phase 1since Nov 26, 2008 | Nov 26, 2008 | none ahead |
| Renovo | 20 open or running | phase 3since Jan 24, 2007 | Jan 24, 2007 | none ahead |
| Amneal Pharmaceuticals | 10 open or running | phase 3since Jan 28, 2013 | Jan 28, 2013 | none ahead |
| ascend-therapeutics | 10 open or running | phase 4since Sep 8, 2005 | Sep 8, 2005 | none ahead |
| biosante-pharmaceuticals | 10 open or running | phase 3since Oct 20, 2006 | Oct 20, 2006 | none ahead |
| centro-a-f-de-estudios-tecnologicos-s-a | 10 open or running | phase 3since Oct 16, 2008 | Oct 16, 2008 | none ahead |
| Corium Innovations | 11 open or running | phase 1since Aug 26, 2026 | Aug 26, 2026 | May 31, 2027phase 1 · NCT07794150 |
| Hamad Medical | 10 open or running | phase 2since Apr 6, 2021 | Apr 6, 2021 | none ahead |
| Lotus Pharmaceutical | 10 open or running | phase 3since Dec 14, 2016 | Dec 14, 2016 | none ahead |
| Padagis | 10 open or running | phase 3since May 10, 2016 | May 10, 2016 | none ahead |
| prasco-llc | 10 open or running | phase 3since Nov 1, 2017 | Nov 1, 2017 | none ahead |
| productos-cienti-ficos-s-a-de-c-v | 10 open or running | phase 1since Feb 10, 2011 | Feb 10, 2011 | none ahead |
| Sun Pharmaceutical Industries | 10 open or running | phase 3since Dec 15, 2012 | Dec 15, 2012 | none ahead |
| upsher-smith-laboratories | 10 open or running | phase 3since Jul 29, 2008 | Jul 29, 2008 | none ahead |
| viramal-limited | 10 open or running | phase 1since Jun 1, 2018 | Jun 1, 2018 | none ahead |
Also a collaborator on its studies: iqvia-pty-ltd, Abbott, simbec-research, laboratoires-besins-international and gru-nenthal-s-a.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 41 studies since Apr 19, 2005.
- May 18, 2015Phase 2 study in DyspareuniaTherapeuticsMD · NCT02449902 · 50 enrolled · United States
- Jan 8, 2016Phase 3 study in LeiomyomaAbbVie · NCT02654054 · 413 enrolled · United States, Canada, Puerto Rico
- Feb 22, 2016Phase 3 study in LeiomyomaAbbVie · NCT02691494 · 378 enrolled · United States, Canada
- May 10, 2016Padagis's first study: phase 3 study in AtrophyNew to PadagisPadagis · NCT02770365 · 695 enrolled · United States
- Dec 14, 2016Lotus Pharmaceutical's first study: phase 3 study in Atrophic VaginitisNew to Lotus PharmaceuticalLotus Pharmaceutical · NCT02995694 · 535 enrolled
- Jul 7, 2017Phase 3 study in EndometriosisAbbVie · NCT03213457 · 681 enrolled · United States, Canada, Puerto Rico
- Aug 31, 2017Phase 3 study in MenorrhagiaAbbVie · NCT03271489 · 478 enrolled · United States, Puerto Rico
- Nov 1, 2017prasco-llc's first study: phase 3 study in PruritusNew to prasco-llcprasco-llc · NCT03332303 · 540 enrolled · United States
- Jun 1, 2018viramal-limited's first study: phase 1 study in MenopauseNew to viramal-limitedviramal-limited · NCT03556800 · 20 enrolled · United Kingdom
- Nov 9, 2018Grünenthal's first study: phase 1 study in BioequivalenceNew to GrünenthalGrünenthal · NCT03749733 · Mexico
- Apr 6, 2021Hamad Medical's first study: phase 2 study in COVID-19New to Hamad MedicalHamad Medical · NCT04853069 · 2,000 enrolled · Qatar
- Apr 5, 2022Phase 1 study in BioequivalenceGrünenthal · NCT05332106 · 10 enrolled · India
- Nov 7, 2022Phase 3 study in DyspareuniaTeva Pharmaceutical Industries · NCT05617820 · 1,050 enrolled · United States, El Salvador, Honduras
- Aug 26, 2026Corium Innovations's first study: phase 1 study in MenopauseNew to Corium InnovationsCorium Innovations · NCT07794150 · 250 planned · United States, India
Ahead
- May 31, 2027Primary completion: phase 1 study in MenopauseCorium Innovations · NCT07794150
TargetBeta
“Estrogen receptor alpha agonist”ChEMBL 37, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
All 55 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07794150Menopause · United States, India | 1 | Recruiting | Corium Innovations | May 31, 2027 | 250 |
| NCT05617820Dyspareunia · United States, El Salvador, Honduras | 3 | Completed | Teva Pharmaceutical Industries | Mar 15, 2024 | 1,050 |
| NCT05332106Bioequivalence · India | 1 | Completed | Grünenthal | Mar 22, 2022 | 10 |
| NCT04853069COVID-19 · Qatar | 2 | UNKNOWN | Hamad Medical | Feb 28, 2022 | 2,000 |
| NCT03749733Bioequivalence · Mexico | 1 | Withdrawn | Grünenthal | Dec 2019 | 0 |
| NCT03556800Menopause · United Kingdom | 1 | UNKNOWN | viramal-limited | Jun 30, 2022 | 20 |
| NCT03332303Pruritus · United States | 3 | Completed | prasco-llc | Mar 15, 2018 | 540 |
| NCT03271489Menorrhagia · United States, Puerto Rico | 3 | Completed | AbbVie | Jun 28, 2024 | 478 |
| NCT03213457Endometriosis · United States, Canada, Puerto Rico | 3 | Completed | AbbVie | Mar 27, 2020 | 681 |
| NCT02995694Atrophic Vaginitis | 3 | Completed | Lotus Pharmaceutical | Dec 2016 | 535 |
| NCT02770365Atrophy · United States | 3 | Completed | Padagis | Nov 2016 | 695 |
| NCT02691494Leiomyoma · United States, Canada | 3 | Completed | AbbVie | Feb 14, 2018 | 378 |
| NCT02654054Leiomyoma · United States, Canada, Puerto Rico | 3 | Completed | AbbVie | Jan 18, 2018 | 413 |
| NCT02449902Dyspareunia · United States | 2 | Completed | TherapeuticsMD | Sep 2013 | 50 |
| NCT02253173Dyspareunia · United States, Canada | 3 | Completed | TherapeuticsMD | Oct 2015 | 764 |
| NCT01942668Hot Flashes · United States | 3 | Completed | TherapeuticsMD | Oct 28, 2016 | 1,845 |
| NCT01845649Dyspareunia · United States | 3 | Completed | AbbVie | Nov 20, 2013 | 550 |
| NCT01779947Atrophic Vaginitis Due to Menopause · United States | 3 | Completed | Amneal Pharmaceuticals | Sep 2012 | 519 |
| NCT01753102Vulvar Atrophy · India | 3 | Terminated | Sun Pharmaceutical Industries | Apr 30, 2013 | 49 |
| NCT01710696Genetic Diseases, Inborn · Spain | 3 | Completed | Novo Nordisk | Jul 26, 2004 | 50 |
| NCT01705249Menopause · Norway, Sweden | 4 | Completed | Novo Nordisk | Jun 6, 2003 | 191 |
| NCT01638910Contraception · China, Hong Kong, India and more | 3 | Completed | Bayer | Nov 2014 | 955 |
| NCT01596010Menopause · Germany | 1 | Completed | Novo Nordisk | Nov 2007 | 44 |
| NCT01486979Menopause · Germany | 1 | Completed | Novo Nordisk | May 2007 | 58 |
| NCT01477632Menopause · Germany | 1 | Completed | Novo Nordisk | Jun 2005 | 24 |
| NCT01455597Vulvovaginal Atrophy · United States | 3 | Completed | AbbVie | Dec 3, 2012 | 309 |
| NCT01400776Postmenopausal Vulvovaginal Atrophy · United States | 3 | Completed | AbbVie | Feb 27, 2012 | 722 |
| NCT01293747Menopause · Mexico | 1 | Completed | productos-cienti-ficos-s-a-de-c-v | Aug 2011 | 30 |
| NCT01181726Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Feb 2007 | 40 |
| NCT01157182Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Apr 2007 | 36 |
| NCT01085877Menopause · Germany | 1 | Completed | Novo Nordisk | May 2010 | 70 |
| NCT01070979Hormone Replacement Therapy · United States | 3 | Completed | AbbVie | Sep 2003 | 249 |
| NCT00984386Cicatrix · United Kingdom | 2 | Completed | Renovo | Apr 2005 | 44 |
| NCT00909857Primary Dysmenorrhea · United States, Canada, Chile and more | 3 | Completed | Bayer | Nov 2010 | 507 |
| NCT00820664Postmenopausal Symptoms | 1 | Completed | Merck | May 2009 | 29 |
| NCT00799708Postmenopause | 1 | Completed | Merck | Oct 2008 | 27 |
| NCT00775242Hot Flashes · Mexico | 3 | Completed | centro-a-f-de-estudios-tecnologicos-s-a | Nov 2008 | 103 |
| NCT00754065Contraception · United States, Canada | 3 | Completed | Bayer | May 10, 2011 | 409 |
| NCT00727129Hot Flashes | 3 | Completed | upsher-smith-laboratories | 495 | |
| NCT00560924Menopause · Sweden | 3 | Terminated | Novo Nordisk | Mar 17, 2004 | 6 |
| NCT00522873Hot Flashes · United States, Argentina, Austria and more | 3 | Completed | Bayer | Aug 2009 | 662 |
| NCT00465192Menopause | 3 | Completed | Novo Nordisk | Nov 30, 1995 | 230 |
| NCT00464971Menopause | 3 | Completed | Novo Nordisk | Nov 30, 1996 | 102 |
| NCT00446199Hot Flashes · United States | 3 | Completed | Bayer | Oct 2008 | 735 |
| NCT00431132Menopause · Czech Republic, Denmark, Finland and more | 3 | Completed | Novo Nordisk | Nov 2008 | 336 |
| NCT00426972Burns · Germany, Latvia, Russian Federation and more | 3 | Completed | Renovo | Jul 2008 | 148 |
| NCT00391417Hot Flashes | 3 | Completed | biosante-pharmaceuticals | 431 | |
| NCT00356447Vasomotor Symptoms · China | 3 | Completed | Bayer | Oct 2007 | 249 |
| NCT00310531Bone Diseases, Metabolic | 3 | Completed | Bayer | 500 | |
| NCT00184795Hot Flashes · Austria, Belgium, Denmark and more | 3 | Completed | Novo Nordisk | May 4, 2005 | 576 |
| NCT00206622Hot Flashes · United States | 4 | Completed | Bayer | 425 | |
| NCT00185328Postmenopause | 4 | Completed | Bayer | 55 | |
| NCT00185237Hot Flashes | 3 | Completed | Bayer | Nov 2006 | 165 |
| NCT00160173Postmenopausal Symptoms · United States | 4 | Completed | ascend-therapeutics | Sep 6, 2005 | 221 |
| NCT00108849Menopause · United States, Canada | 3 | Completed | Novo Nordisk | May 2007 | 309 |
How it is read
Names in the registry
- “Estradiol”, 7 entries
- “NOMAC-E2”, 6 entries
- “estradiol, 25 mcg”, 5 entries
- “estradiol, 10 mcg”, 4 entries
- “Zesteem”, 4 entries
Conditions, from the studies’ own filings
- Hot Flashes, 9 studies
- Dyspareunia, 4 studies
- Atrophic Vaginitis, 2 studies
- Leiomyoma, 2 studies
- Menorrhagia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.